obesity drug news today glp-1 Antagonists Increase Plan Spend - What's Next The GLP-1 Access Gap: Mapping

Description

95% CI, 0.46-0.61

However, these results should be interpreted considering the studys limitations, including its retrospective design, the absence of a control group, and the potential for selection bias

Cost-effectiveness of once daily GLP-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in Norway

Campbell JE

Cardiovascular Outcomes This section reviews current evidence regarding GLP-1 RAs effects on MACE, PAD, CAD, HF, blood pressure, and AF, with detailed findings of trials and meta-analyses discussed in Tables 1 and 2 Major Adverse Cardiac Events Among Patients with T2DM Strong evidence supports using GLP-1 RAs to reduce MACE among patients with T2DM and established CVD